Call +44 (0)1904 798634 or +44 (0)7550 079918

Leading provider of life science market reports and research services

Molecular Diagnostics: A Global End-User Study

Be the first to review this product

A Global Market Study of End-User Current Practices and Three-Year Plans, Growth, Developments and New Opportunities
You can choose to pay by purchase order during checkout

Availability: In stock

$5,800.00

* Required Fields

You can choose to pay by purchase order during checkout
Laboratory Markets Ltd

Digital downloads direct to your inbox within 24 hours.

First class customer service from our team of experts.

Pay by credit card or request an invoice

Product Description

Details

Laboratory Markets has carried out a comprehensive market study of molecular diagnostics that involved the participation of 453 experienced end-users. This market study profiled current practices, developments, trends and three-year plans, as well as growth and opportunities across key sectors of the clinical-user and research-use market areas. These areas include growth, market-size estimates for molecular diagnostics sample processing, molecular diagnostics instrument suppliers, molecular diagnostics consumables suppliers, clinical and research use of molecular diagnostics, applications, molecular diagnostics techniques, disease areas, multiplexing, molecular forms, end-user's future needs, relative running costs, study samples, disease biomarkers, per-sample costs, sample throughputs, organisation types, countries and regions and roles of end-users.

Molecular Diagnostics Market Study

  • Growth in use of molecular diagnostics now and anticipated in 3 years (±%) 
  • High-growth areas of molecular diagnostics now and anticipated in 3 years (±%) 
  • End-users' three-year plans for their use of molecular diagnostics 
  • Molecular diagnostics applications now and anticipated in 3 years (±%) 
  • Molecular diagnostics instrument suppliers now and anticipated in 3 years (±%) 
  • Molecular diagnostics consumables suppliers now and anticipated in 3 years (±%) 
  • Clinical and research use of molecular diagnostics, now and anticipated in 3 years (±%) 
  • Molecular diagnostics techniques now and anticipated in 3 years (±%) 
  • Disease Areas relating to molecular diagnostics, now and anticipated in 3 years (±%)
  • Multiplexing in molecular diagnostics, now and anticipated in 3 years (±% change) 
  • Molecular forms in molecular diagnostics, now and anticipated in 3 years (±%)
  • Study Samples investigated in molecular diagnostics
  • Per-sample costs in molecular diagnostics, estimated by end-users
  • End-user's sample throughputs in molecular diagnostics
  • Future needs relating to end-users' use of molecular diagnostics 
  • Sample types analysed using molecular diagnostics
  • Molecular diagnostics disease biomarkers, purposes and utilities 
  • Relative molecular diagnostics running costs 
  • Costs of sample analysis estimated by end users, using molecular diagnostics 
  • Average monthly throughput of samples using molecular diagnostics 
  • Countries and global regions

This Report

Laboratory Markets' specialised market studies are designed to assist suppliers and developers to profile current and evolving laboratory market opportunities. All of our studies are carried out through specialist groups of experienced end-users and therefore findings are based on 'real world' market data. By providing new insights and a better understanding of end-user practices, needs and future plans, our studies assist suppliers to sell into these markets, and also support innovation and strategic planning. The following study areas were investigated:

Growth

Based on recent trends in the numbers of molecular diagnostic tests carried out in their laboratories, end-users' own estimates of by how much (% increase or % decrease) their laboratory use of molecular diagnostics has changed over the last three years. Also, based on current trends in the numbers of samples analysed in their laboratories, end-users' own estimates of by how much (% increase or % decrease) they anticipate their laboratory use of molecular diagnostics will change over the next three years.

Molecular Diagnostics Instrument Suppliers ++

End-users' current molecular diagnostics instruments suppliers and those suppliers they anticipate will be supplying their molecular diagnostics instruments in three years time, where the companies++ considered were A&A Biotechnology, AB ANALITICA, Abbott Molecular, Abcam, AccuGenomics, AdvanDx, Affymetrix, Agendia, Agilent, Ameripath, Amoy Diagnostics, Amplisens, APB, Applied BioCode, Applied BioSystems (ABI), Arcxis Biotechnologies, Argene Inc (Biomerieux), Arrayit, Asuragen, Atlas Genetics, AutoGenomics, Bayer, BD, Beckman Coulter, Biocartis, Biocept, Biodynamics, Biodyne, BioGenex, Biognost, BioHelix, Bioline, BioMerieux, Bioneer, Bio-Rad, Cancer Genetics, Caris Life Sciences, Cell Signaling Technology, Cell-Marque, Cepheid, Clarient, Conda, Cooperative Diagnostics, Cytocell, Dako (Agilent), DDL, DermTech, ELITech Molecular, Empire Genomics, Epigenomics, Eppendorf, Eurofins, Euroimmun, Experteem, Falcon Genomics, Fast track Diagnostics, Fermantas, Focus Diagnostics, Foundation Medicine, GE Healthcare, Geneworks, GenMark Diagnostics, Genomica, Gen-Probe (Hologic), Gold Standard Diagnostics, Hain Life Science, Hemogenomics, Hologic, Hylabs, Idaho Technology, IDEXX, IDT, IDVET, Illumina, INEP, In-House Developed, Integrated Biotherapeutics, Interpath, Invitrogen (Life Technologies), Ipsogen (Qiagen), Kreatech Diagnostics, Lectinity, Leica, Life Technologies, Luminex, Macherey-Nagel, MDxHealth, Merck, Meridian Bioscience, Metabion, Millipore, Mobio, MolecularMD, MRC-Holland, Myriad Genetics, Nanosphere, NeoGenomics, New England Biolabs, Novartis Diagnostics, Optigene, Orion Genomics, OvaGene Oncology, Oxoid, Palex, Pathology, PrimeraDx, Promega, Qiagen, Quidel, R-Biopharm Inc, Roche Diagnostics, Sacace Biotechnologies, Santacruz, Seegene, SensiGen, Serosep Ltd., Siemens, Sigma-aldrich, SinaGen, Stratagene, Synbiotics, Sysmex, Takara, Thermo Fisher, TiBMolBiol, Ventana (Roche), Vircell, Virion, Vivantis, Zymo and any others.

Molecular Diagnostics Consumables Suppliers ++

End-users' current molecular diagnostics consumables suppliers and those suppliers they anticipate will be supplying their molecular diagnostics consumables in three years time, where the companies++ considered were A&A Biotechnology, AB ANALITICA, Abbott Molecular, Abcam, AccuGenomics, AdvanDx, Affymetrix, Agendia, Agilent, Ameripath, Amoy Diagnostics, Amplisens, APB, Applied BioCode, Applied BioSystems (ABI), Arcxis Biotechnologies, Argene Inc (Biomerieux), Arrayit, Asuragen, Atlas Genetics, AutoGenomics, Bayer, BD, Beckman Coulter, Biocartis, Biocept, Biodynamics, Biodyne, BioGenex, Biognost, BioHelix, Bioline, BioMerieux, Bioneer, Bio-Rad, Cancer Genetics, Caris Life Sciences, Cell Signaling Technology, Cell-Marque, Cepheid, Clarient, Conda, Cooperative Diagnostics, Cytocell, Dako (Agilent), DDL, DermTech, ELITech Molecular, Empire Genomics, Epigenomics, Eppendorf, Eurofins, Euroimmun, Experteem, Falcon Genomics, Fast track Diagnostics, Fermantas, Focus Diagnostics, Foundation Medicine, GE Healthcare, Geneworks, GenMark Diagnostics, Genomica, Gen-Probe (Hologic), Gold Standard Diagnostics, Hain Life Science, Hemogenomics, Hologic, Hylabs, Idaho Technology, IDEXX, IDT, IDVET, Illumina, INEP, In-House Developed, Integrated Biotherapeutics, Interpath, Invitrogen (Life Technologies), Ipsogen (Qiagen), Kreatech Diagnostics, Lectinity, Leica, Life Technologies, Luminex, Macherey-Nagel, MDxHealth, Merck, Meridian Bioscience, Metabion, Millipore, Mobio, MolecularMD, MRC-Holland, Myriad Genetics, Nanosphere, NeoGenomics, New England Biolabs, Novartis Diagnostics, Optigene, Orion Genomics, OvaGene Oncology, Oxoid, Palex, Pathology, PrimeraDx, Promega, Qiagen, Quidel, R-Biopharm Inc, Roche Diagnostics, Sacace Biotechnologies, Santacruz, Seegene, SensiGen, Serosep Ltd., Siemens, Sigma-aldrich, SinaGen, Stratagene, Synbiotics, Sysmex, Takara, Thermo Fisher, TiBMolBiol, Ventana (Roche), Vircell, Virion, Vivantis, Zymo and any others.

++ This listing of suppliers may include companies that have been acquired by other companies, changed their names, or moved out of this field and transferred their products to a third party. This is because, in our experience, end-users often refer to original supplier's and product names, even when companies have been acquired, changed their company name, or where a product range is made available through an alternative third party

Clinical and Research Use of Molecular Diagnostics

This study independently analysed both the clinical and research use of molecular diagnostics across the market areas presented.

Applications

End-users' current applications of molecular diagnostics those applications they anticipate they will be using in three years time, where the applications considered were Disease research, Diagnostics research, Disease risk management, Treatment decisions, Clinical diagnostics, Diagnostic screening, Clinical Therapeutics, Clinical Diagnostics, Drug R&D, Veterinary, Genetics, Genomics, Plants and any others.

Molecular Diagnostics techniques

End-users' current molecular diagnostics techniques and those techniques they anticipate they will be using in three years time, where the techniques considered were Allele-specific PCR, Arbitrarily Primed PCR (AP-PCR), Assembly PCR (Polymerase Cycling Assembly, PCA), Asymmetric PCR (A PCR), bDNA assays, Bead-Emulsion Amplification PCR (BEA), Cancer BioChip System, Classical qualitative PCR, Colony PCR, Comet assay, Conventional qualitative PCR, Cycling Probe Technology, Cytogenetic banding, Degenerate Oligonucleotide PCR (DOP-PCR), Denaturing Gradient Gel Electrophoresis (DGGE), Digital PCR (dPCR), DNA biosensors, DNA cloning, General Hybridization, General Primers PCR, Genome Expression Profiling System (GeXP), Helicase-Dependent Amplification, High resolution melting (HRM), Hot start PCR, Hybrid Capture Assay, Hyper-PCR, Immunocapture PCR, In Situ Hybridization (e.g. FISH), In-Silico PCR, Intersequence-specific PCR (ISSR), Inverse PCR, Isothermal PCR, Karyotyping (chromosomes), Ligase Chain Reaction, Ligation-Mediated PCR, Liquid Hybridization, Long PCR, Loop-mediated isothermal amplification (LAMP), Methylation-Specific PCR (MSP), Microarrays, Microsphere-Based Array, Miniprimer PCR, Multilocus Sequence Typing (MLST), Multiple Loci VNTR Analysis (MLVA), Multiplex Ligation-Dependent Probe Amplification (MLPA), Multiplex PCR, Multiplex Real-Time PCR, Multiplex Taqman, Multiplexed Microsphere-Based Array, Nested PCR, Next-Generation Sequencing (NGS), Northern Blot, Nucleic Acid Sequence-Based Amplification (NASBA), Overlap-Extension PCR ( Splicing by overlap extension, SOE), PAN-AC (Single Reaction Real Time PCR), Panbacterial PCR, PCR array, PCR Denaturing Gradient Gel Electrophoresis (PCR DGGE), PCR Restriction Fragment Length Polymorphism (PCR-RFLP), Phylogenetic Community Analysis, Pulsed Field Gel Glectrophoresis (PFGE), Random Amplified Polymorphic DNA (RAPD), Rapid Amplification of cDNA ENDS PCR (RACE PCR), Rapid test, Restriction Fragment Length Polymorphism (RFLP), Reverse Transcription PCR (RT-PCR), Sanger sequencing, Single molecule PCR, Single nucleotide repeat (SNR), Single Specific Primer-Polymerase Chain Reaction (SSP-PCR), Single tube Nested-PCR, Solid Phase PCR, Southern Blot, Stem loop RT PCR, Stepdown PCR, Strand Displacement Amplification, TaqMan Real Time PCR, Real Time/Quantitative PCR (qPCR), Techniques not requiring amplification, Temporal Temperature Gradient Gel Electrophoresis (PCR-TTGE), Thermal Asymmetric Interlaced PCR (TAIL-PCR), Touchdown PCR, Transcription-Mediated Amplification (TMA), Type-Specific PCR, Universal Fast Walking and any others.

Disease Areas

The diseases or disease areas currently studied by end-users using molecular diagnostics and those diseases or disease areas they anticipate studying with molecular diagnostics in three years from now, where the diseases or diseases areas considered were Ageing, Allergy, Arthritis, Asthma, Autoimmune, Bacterial infections, Blood diseases, Bone, Bone metabolism, Brain damage, Cancer, Cardiac, Cardiometabolic, Cardiovascular, Cartilage, Celiac Disease, Central nervous system, Coagulation, Connective Tissue, Dermatology, Diabetes, Endocrinology, Epidemiology, Fertility, Food Intolerance, Fungal infections, Gastrointestinal, Genetic diseases, Genito-urinary system, Haematology, Hepatitis, Hypertension, Immune system, Inflammation, Liver Disease, Metabolic disorders, Musculoskeletal disorders, Neurodegenerative diseases, Neuromuscular, Newborn screening, Nutrition, Obesity, Obstetrics and Gynaecology, Ophthalmology, Pain, Parasitology, Plant Health, Pregnancy, Reproduction, Respiratory, Sexually Transmitted, Skin, Smoking, Thrombosis/Coagulation, Thyroid Diseases, Toxicology, Tropic al Diseases, Vascular disease, Vasculitis, Veterinary, Viral infections, Vitamin deficiencies, Women's Health and any others.

Multiplexing

The levels of multiplexing in molecular diagnostics currently studied by end-users and those levels of multiplexing that end-users anticipate using in molecular diagnostics in three years from now, where the levels of multiplexing considered were 1 (no multiplexing), 2 to 3, 3 to 5, 11 to 15, 16 to 20, 21 to 30, 31 to 40, 41 to 50, 51 to 60, 61 to 70, 71 to 80, 81 to 90, 91 to 100, 101 to 150, 151 to 200.

Molecular Forms

The molecular forms investigated by end-users currently using diagnostics and those molecular forms that end-users anticipate investigating in three years from now, where the molecular forms considered were Genomic DNA, Long non-coding RNAs (lncRNA), Messenger RNA (mRNA), MicroRNA, Ribosomal DNA (rRNA), Small Interfering RNA (siRNA), Small Nuclear RNA (snRNA), Transfer RNA (tRNA) and any others.

Future Needs

End-users' areas of greatest future need or innovation based on their own use of molecular diagnostics, where the areas of need or innovation considered were Accuracy, Ambiguities, Applicability to 'difficult' samples, Consistency, Convenience, Cost, Data interpretation, Ease of use, Extraction times, Multiplex capabilities, Immunoassay run times, Reagent degradation, Reliability, Robustness, Safety, Sensitivity, Service support, Size footprint, Software capabilities, Speed, Stability, Throughput, Versatility and any other.

Relative Running Costs

End-users' relative running costs in their use of molecular diagnostics, where the cost areas considered were Molecular diagnostics kits and reagents, External services costs, Instrument service (maintenance) contracts, Plasticware (tips, tubes etc), Sample preparation (extraction) kits and reagents, Software licenses or other areas

Study Samples

The main samples with which end-users work in molecular diagnostics, where the sample types considered were Apheresis samples, Ascitic fluids, Bacteria-containing samples, Bone Marrow, Broncho-alveolar lavage, Cell culture, Cell lines, Cerebrospinal fluid, Ex vivo cell cultures, Fat, Forensic samples, Isolated blood cells (e.g. platelets), Isolated stem or progenitor cells, Lymph, Microbiological materials, Milk, Plasma, Saliva, Semen, Serum, Small multicellular organisms, Smears from surfaces, Spermatozoa, Sputum, Synovial fluids, Tissue biopsies, Tissues, Tumour tissues, Urine, Virus-containing samples, Whole blood and any others.

Disease Biomarkers

The purpose(s) of end-users' use of molecular diagnostic disease biomarker studies, where the areas considered were Biomarker Discovery, Clinical _ Research, Clinical _ Trials, Diagnostics _ Screening, Diagnostics _ Research, Diagnostics _ Routine tests, Disease research, Drug R&D _ Clinical trials, Drug R&D _ Drug targets, Drug R&D _ Preclinical, Drug R&D _ ADME, Toxicology, Treatment _ Decisions, Treatment _ Monitoring and any others.

The clinical utilities of end-user's molecular diagnostic disease biomarker studies, where the clinical utilities considered were Companion diagnostics, Disease prognosis, Disease stage or severity, Disease susceptibility or risk, Disease variability, Drug discovery, Drug therapy dose, Early detection of disease, Guiding treatment, Multiple utilities, Response to therapy, Safety or toxicity factors, Screening and monitoring, Therapy decision-making and any other.

Per-Sample Costs

End-users' estimates of the average costs of their molecular diagnostics tests for a typical study sample in their laboratory, where the cost levis considered <$5, $5 - $10, $10 - $20, $20 - $30, $30 - $40, $40 - $50, $50 - $70, $70 - $100, $100 - $150, $150 - $250, $250 - $400, $400 - $600, $600 - $1000 and > $1000.

Sample Throughputs

End-users' estimates of the average number of molecular diagnostics runs (samples analysed) each month in their laboratory, where the numbers of samples considered were <10, 10 to 20, 20 _ 30, 30 _ 40, 40 _ 50, 50 _ 70, 70 _ 100, 100 _ 150, 150 _ 250, 250- 400, 400 _ 600, 600 _ 1000, 1000 _ 1500, 1500 _ 2000, 2000 _ 2500 and > 2500.

Molecular Diagnostics End-Users

Organisation Types: Molecular diagnostics end-users' organisation type, where the options were Clinic, Government Organisation, Hospital, Large International Company, Medium Sized Company, Research Institute, Small Company, Teaching Hospital, University, Veterinary Organisation or other.

Experience: End-users' years of experience using molecular diagnostics

Job Title: End-users' job title, role and main activities.

Countries and Regions: Molecular diagnostics Immunoassay end-users' countries and global regions; Asia, North America, South America, Africa (Sub-Saharan), Central America/Caribbean, Australia, New Zealand and Oceania and Middle East/North Africa/and Greater Arabia.
Participants: Names and organisations.

Overall Role: End-users' role relating to their use of molecular diagnostics, where the roles considered were Clinical Use (for patients), Research use, Veterinary Use and other areas.

Additional Information

Additional Information

Publisher name Laboratory Markets Ltd
Format PDF
Page count 136
Publication date 5 Jan 2016
Table of contents 1. Introduction

1.1. This Chapter

1.2. Background

1.3. Market Questions

2. Participants

2.1. This Chapter

2.2. Global Regions

Figure 2.1. Global regions of participants in Molecular Diagnostics 2015
Table 2.1. Global regions of participants in Molecular Diagnostics 2015

2.3. Countries

Figure 2.2. Top ten countries of participants in Molecular Diagnostics 2015
Table 2.2. Countries of participants in Molecular Diagnostics 2015

2.4. Job Title

Figure 2.3. Top 10 job titles of participants in Molecular Diagnostics 2015
Table 2.3. Titles of participants in Molecular Diagnostics 2015

2.5. Experience

Figure 2.4. Top ten experience levels of participants in Molecular Diagnostics 2015
Table 2.4. Experience of participants in Molecular Diagnostics 2015

2.6. Organisation Type

Figure 2.5. Organisation types of participants in Molecular Diagnostics 2015
Table 2.5. Organisation types of participants in Molecular Diagnostics 2015

2.7. Fields

Figure 2.6. Fields of participants in Molecular Diagnostics 2015
Table 2.6. Fields of participants in Molecular Diagnostics 2015

2.8. Role

Figure 2.7. Roles of participants in Molecular Diagnostics 2015
Table 2.7. Roles of participants in Molecular Diagnostics 2015

2.9. Discussion

3. Clinical Use of Molecular Diagnostics

3.1. This Chapter

3.2. Market Question(s)

3.3. Current Molecular Diagnostics Applications

Figure 3.1. Top ten current molecular diagnostics applications, of participants (clinical use)
Table 3.1. Current molecular diagnostics applications, of participants (clinical use)

3.4. Future Molecular Diagnostics Applications

Figure 3.2. Top ten anticipated future molecular diagnostics applications, of participants (clinical use)
Table 3.2. Anticipated future molecular diagnostics applications, of participants (clinical use)

3.5. Current Diseases

Figure 3.3. Top ten current diseases studied using molecular diagnostics, of participants (clinical use)
Table 3.3. Current diseases studied using molecular diagnostics, of participants (clinical use)

3.6. Future Diseases

Figure 3.4. Top ten anticipated future diseases studied using molecular diagnostics, of participants (clinical use)
Table 3.4. Anticipated future diseases studied using molecular diagnostics, of participants (clinical use)

3.7. Current Molecular Diagnostics Techniques

Figure 3.5. Top ten current molecular diagnostics techniques used, by participants (clinical use)
Table 3.5. Current molecular diagnostics techniques used, by participants (clinical use)

3.8. Future Molecular Diagnostics Techniques

Figure 3.6. Top ten anticipated future molecular diagnostics techniques, of participants (clinical use)
Table 3.6. Anticipated future molecular diagnostics techniques, of participants (clinical use)

3.9. Current Multiplex Assays

Figure 3.7. Top ten current molecular diagnostics multiplex levels, used by participants (clinical use)
Table 3.7. Current molecular diagnostics multiplex levels, used by participants (clinical use)

3.10. Future Multiplex Assays

Figure 3.8. Top ten anticipated future multiplex assay levels used by participants (clinical use)
Table 3.8. Anticipated future multiplex assay levels used by participants (clinical use)

3.11. Study Samples

Figure 3.9. Top ten study samples used by participants (clinical use)
Table 3.9. Study samples used by participants (clinical use)

3.12. Current Instrument Suppliers

Figure 3.10. Top ten current molecular diagnostics instrument suppliers, of participants (clinical use)
Table 3.10. Current molecular diagnostics instrument suppliers, of participants (clinical use)

3.13. Future Instrument Suppliers

Figure 3.11. Top ten anticipated future molecular diagnostics instrument suppliers, of participants (clinical use)
Table 3.11. Anticipated future molecular diagnostics instrument suppliers, of participants (clinical

3.14. Current Consumables Suppliers

Figure 3.12. Top ten current molecular diagnostics consumables suppliers, of participants (clinical use)
Table 3.12. Current molecular diagnostics consumables suppliers, of participants (clinical use)

3.15. Future Consumables Suppliers

Figure 3.13. Top ten anticipated future molecular diagnostics consumables suppliers, of participants (clinical use)
Table 3.13. Anticipated future molecular diagnostics consumables suppliers, of participants (clinical

3.16. Current Molecular Forms

Figure 3.14. Top ten current molecular forms studied, by participants (clinical use)
Table 3.14. Current molecular forms studied, by participants (clinical use)

3.17. Future Molecular Forms

Figure 3.15. Top anticipated future molecular forms, of participants (clinical use)
Table 3.15. Anticipated future molecular forms, of participants (clinical use)

3.18. Needs/Innovation Requirements

Figure 3.16. Top ten molecular diagnostics needs or innovation requirements, of participants (clinical use)
Table 3.16. Molecular diagnostics needs or innovation requirements, of participants (clinical use)

3.19. Running Costs

Figure 3.17. Top molecular diagnostics relative running costs, of participants (clinical use)
Table 3.17. Molecular diagnostics relative running costs, of participants (clinical use)

4. Research Use of Molecular Diagnostics

4.1. This Chapter

4.2. Market Question(s)

4.3. Current Molecular Diagnostics Applications

Figure 4.1. Top ten current molecular diagnostics applications, of participants (research use)
Table 4.1. Current molecular diagnostics applications, of participants (research use)

4.4. Future Molecular Diagnostics Applications

Figure 4.2. Top ten anticipated future molecular diagnostics applications, of participants (research use)
Table 4.2. Anticipated future molecular diagnostics applications, of participants (research use)

4.5. Current Diseases

Figure 4.3. Top ten current diseases studied using molecular diagnostics, of participants (research use)
Table 4.3. Current diseases studied using molecular diagnostics, of participants (research use)

4.6. Future Diseases

Figure 4.4. Top ten anticipated future diseases studied using molecular diagnostics, of participants (research use)
Table 4.4. Anticipated future diseases studied using molecular diagnostics, of participants (research use)

4.7. Current Molecular Diagnostics Techniques

Figure 4.5. Top ten current molecular diagnostics techniques used, by participants (research use)
Table 4.5. Current molecular diagnostics techniques used, by participants (research use)

4.8. Future Molecular Diagnostics Techniques

Figure 4.6. Top ten anticipated future molecular diagnostics techniques, of participants (research use)
Table 4.6. Anticipated future molecular diagnostics techniques, of participants (research use)

4.9. Current Multiplex Assays

Figure 4.7. Top ten current molecular diagnostics multiplex levels, used by participants (research use)
Table 4.7. Current molecular diagnostics multiplex levels, used by participants (research use)

4.10. Future Multiplex Assays

Figure 4.8. Top ten anticipated future multiplex assay levels used by participants (research use)
Table 4.8. Anticipated future multiplex assay levels used by participants (research use)

4.11. Study Samples

Figure 4.9. Top ten study samples used by participants (research use)
Table 4.9. Study samples used by participants (research use)

4.12. Current Instrument Suppliers

Figure 4.10. Top ten current molecular diagnostics instrument suppliers, of participants (research use)
Table 4.10. Current molecular diagnostics instrument suppliers, of participants (research use)

4.13. Future Instrument Suppliers

Figure 4.11. Top ten anticipated future molecular diagnostics instrument suppliers, of participants (research use)
Table 4.11. Anticipated future molecular diagnostics instrument suppliers, of participants (research

4.14. Current Consumables Suppliers

Figure 4.12. Top ten current molecular diagnostics consumables suppliers, of participants (research use)
Table 4.12. Current molecular diagnostics consumables suppliers, of participants (research use)

4.15. Future Consumables Suppliers

Figure 4.13. Top ten anticipated future molecular diagnostics consumables suppliers, of participants (research use)
Table 4.13. Anticipated future molecular diagnostics consumables suppliers, of participants (research

4.16. Current Molecular Forms

Figure 4.14. Top ten current molecular forms studied, by participants (research use)
Table 4.14. Current molecular forms studied, by participants (research use)

4.17. Future Molecular Forms

Figure 4.15. Top anticipated future molecular forms, of participants (research use)
Table 4.15. Anticipated future molecular forms, of participants (research use)

4.18. Needs/Innovation Requirements

Figure 4.16. Top ten molecular diagnostics needs or innovation requirements, of participants (research use)
Table 4.16. Molecular diagnostics needs or innovation requirements, of participants (research use)

4.19. Running Costs

Figure 4.17. Top molecular diagnostics relative running costs, of participants (research use)
Table 4.17. Molecular diagnostics relative running costs, of participants (research use)

5. Molecular Diagnostics Growth Trends

5.1. This Chapter
5.2. Market Question(s)

5.3. Recent Growth Trends

Figure 5.1. Top ten recent molecular diagnostic's growth trends, of participants
Table 5.1. Recent molecular diagnostic's growth trends, of participants

5.4. Future Growth Trends

Figure 5.2. Top ten anticipated future molecular diagnostic's growth trends, of participants
Table 5.2. Anticipated future molecular diagnostic's growth trends, of participants

6. Molecular Diagnostics and Disease Biomarkers

6.1. This Chapter

6.2. Market Question(s)

6.3. Purpose of Biomarker Studies

Figure 6.1. Top ten purposes of biomarker studies, of participants
Table 6.1. Purposes of biomarker studies, of participants

6.4. Biomarker Clinical Utilities

Figure 6.2. Top ten clinical utilities of biomarkers, of participants
Table 6.2. Clinical utilities of biomarkers, of participants

7. Molecular Diagnostics Per-Sample Costs

7.1. This Chapter

7.2. Market Question(s)

7.3. Cost of Molecular Diagnostics

Figure 7.1. Top ten per-sample cost estimates for molecular diagnostics, of participants
Table 7.1 Per-sample cost estimates for molecular diagnostics, of participants

8. Molecular Diagnostics Per-Sample Costs

8.1. This Chapter

8.2. Market Question(s)

8.3. Molecular Diagnostics Throughput

Figure 8.1. Top ten molecular diagnostics sample throughput estimates, of participants
Table 8.1. Molecular diagnostics sample throughput estimates, of participants

9. Discussion

Reviews

Write Your Own Review

Only registered users can write reviews. Please, log in or register